What Is Provenge?

Provenge (sipuleucel-T) is an FDA-approved autologous cellular immunotherapy — meaning the medication is made individually for you using your own immune cells. It was the first cellular immunotherapy approved for any cancer in the United States and remains a unique option for men with advanced prostate cancer.

Unlike traditional chemotherapy or hormonal therapy, Provenge does not directly poison cancer cells. Instead, it teaches your immune system to recognize prostatic acid phosphatase (PAP) — a protein found in most prostate cancer cells — and mount a targeted immune response against the tumor.

FDA-Approved Indication

Provenge is approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) — prostate cancer that has spread beyond the prostate and has progressed despite hormone therapy, but is not causing significant pain or major symptoms yet.

How Provenge Works

Provenge is a personalized therapy created in three steps over approximately 4 weeks. The cycle is repeated three times — yielding three custom-made infusions.

1. Cell Collection (Leukapheresis)

  • Performed at a blood-collection center about 3 days before each infusion
  • A small IV is placed in each arm
  • Blood is drawn from one arm, immune cells are filtered out, and the rest of the blood is returned through the other arm
  • Procedure takes 3–4 hours

2. Cell Activation in the Lab

  • Your immune cells are sent to a specialized manufacturing facility
  • They are exposed to a recombinant protein (PA2024) that combines PAP with an immune-stimulating signal (GM-CSF)
  • This "trains" your dendritic cells to recognize and target prostate cancer
  • The activated cells are returned within ~3 days

3. Infusion

  • The activated cells are infused back into your vein at our clinic
  • Infusion takes about 60 minutes
  • You are observed for 30 minutes afterward
  • You go home the same day

Total Treatment Course

Three complete cycles (collection → activation → infusion), spaced approximately 2 weeks apart, for a total treatment course of about 4 weeks. After the third infusion, the course is complete — there is no maintenance dosing.

Who Is a Candidate?

Ideal Candidates

  • Metastatic prostate cancer (spread to bone, lymph nodes, or other organs)
  • Castration-resistant — disease has progressed despite testosterone-lowering therapy
  • Asymptomatic or minimally symptomatic — no significant cancer-related pain
  • Adequate immune system and overall health
  • Life expectancy of at least 6 months

May Not Be Ideal For

  • Significant cancer-related pain (other treatments may be needed first)
  • Visceral (liver, lung) metastases with rapid progression
  • Major immune compromise (e.g., active immunosuppressants)
  • Severe cardiovascular disease that limits leukapheresis
  • Concurrent chemotherapy (Provenge is generally given before chemo)

Treatment sequencing matters. Provenge tends to work best earlier in the course of mCRPC — before pain and visceral spread develop. We work closely with your medical oncologist to time it appropriately within the broader sequence of advanced-prostate-cancer therapies.

What Are the Results?

Provenge was approved based on the landmark IMPACT trial, a randomized phase 3 study of more than 500 men with mCRPC.

Outcome Result
Median overall survival benefit ~4.1 months longer than placebo (25.8 vs. 21.7 months)
3-year survival 31.7% vs. 23.0% with placebo
Reduction in risk of death ~22%
PSA decline Less common than other therapies — Provenge does not typically lower PSA dramatically

A Note on PSA

Unlike chemotherapy or hormonal therapy, Provenge often does not cause a large drop in PSA. Yet survival is still extended. The benefit appears to come from a slow, sustained immune response rather than rapid tumor killing — a different mechanism than other prostate-cancer therapies.

Side Effects

Provenge is generally very well tolerated. Most side effects occur within 1–2 days of an infusion and resolve quickly.

Common (≥15%)

  • Chills
  • Fatigue
  • Fever
  • Back pain
  • Nausea
  • Joint aches
  • Headache

Uncommon but Serious

  • Acute infusion reactions (managed during the visit)
  • Stroke or heart attack — rare; risk discussed with your oncologist
  • Catheter or vascular-access complications during leukapheresis
  • Infection at the IV site

Pre-medications such as acetaminophen and an antihistamine are typically given before each infusion to reduce flu-like symptoms.

What to Expect During Treatment

Before Each Infusion (Days −3 to 0)

  • Pre-infusion blood work and review
  • Leukapheresis at a designated center
  • Cells shipped to the manufacturing facility

Infusion Day

  • Pre-medications (acetaminophen, antihistamine)
  • ~60-minute IV infusion of your activated immune cells
  • 30-minute monitoring period
  • Same-day discharge home

Between Infusions

  • Continue testosterone-lowering therapy unless directed otherwise
  • Manage side effects with your team — most resolve in 1–2 days
  • Stay well hydrated

Total treatment course: approximately 4 weeks, with three complete cycles.

Frequently Asked Questions

Will Provenge cure my prostate cancer?

No. Provenge is not a cure. It is one of several life-extending therapies for advanced prostate cancer. The goal is to extend survival and quality of life, often as part of a longer sequence of treatments.

Can I have Provenge with other treatments?

Provenge is most often given before chemotherapy and concurrently with testosterone-lowering therapy. Other AR-targeted agents (such as abiraterone or enzalutamide) may be used before, after, or — in selected cases — alongside Provenge. Sequencing is individualized.

Why doesn't my PSA drop much?

Immunotherapies act differently than chemotherapy. PSA may not change dramatically even though survival is extended. We monitor imaging, symptoms, and PSA trends together rather than relying on PSA alone.

How is leukapheresis different from a regular blood draw?

Leukapheresis filters specific immune cells out of the blood and returns the rest to you. It takes longer (3–4 hours) but uses standard IVs and is performed in a comfortable, supervised setting.

Is Provenge covered by insurance?

Yes. Provenge is covered by Medicare and most private insurance plans for FDA-approved indications. Our team handles prior authorization and confirms coverage before treatment begins.

Personalized Treatment for Advanced Prostate Cancer

If you have advanced prostate cancer, Provenge may add meaningful months — or longer — to your life with a manageable side-effect profile. Our team coordinates closely with leukapheresis centers, the manufacturing partner, and your medical oncologist to make the entire course as smooth as possible.

  • ✅ Personalized cellular immunotherapy
  • ✅ Three outpatient infusions over 4 weeks
  • ✅ Coordinated with hormonal and chemotherapy plans
  • ✅ Insurance verification handled by our team
Schedule Your Consultation

Call 678-344-8900 to speak with our advanced-prostate-cancer team